
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
about 27 years ago
Participating Facultyabout 27 years ago
Introductionabout 27 years ago
Challenges in the Management of Otitis Mediaabout 27 years ago
Selected Abstractsabout 27 years ago
Bibliography





